Announcements
Eurosurveillance remains in the updated list of the Directory of Open Access Journals (DOAJ). It was first added to the DOAJ on 9 September 2004. Eurosurveillance is also listed in the Securing a Hybrid Environment for Research Preservation and Access / Rights MEtadata for Open archiving (SHERPA/RoMEO) [2], a database which uses a colour‐coding scheme to classify publishers according to their self‐archiving policy and to show the copyright and open access self-archiving policies of academic journals. Eurosurveillance is listed there as a ‘green’ journal, which means that authors can archive pre-print (i.e. pre-refereeing), post-print (i.e. final draft post-refereeing) and archive the publisher's version/PDF.

ESCAIDE participants are invited to the fifth Eurosurveillance scientific seminar on 30 November 2016

Follow Eurosurveillance on Twitter: @Eurosurveillanc

Read our articles on Zika virus infection

Read our articles on mcr-1-mediated colistin resistance

Note of concern published for 'Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015', http://bit.ly/29QFXPp


In this issue


Home Eurosurveillance Weekly Release  2001: Volume 5/ Issue 22 Article 4
Back to Table of Contents
Previous
Next

Eurosurveillance, Volume 5, Issue 22, 31 May 2001
Articles

Citation style for this article: Handysides S. Hospital acquired fluoquinolone resistant salmonellosis in the United States. Euro Surveill. 2001;5(22):pii=1744. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=1744

Hospital acquired fluoquinolone resistant salmonellosis in the United States

The New England Journal of Medicine reported an outbreak of fluoroquinolone resistant salmonella infection last week (1). The report raises several important issues – infection control in hospitals and nursing homes, the potential for importation of infection, and caution in the use of antibiotics.

A prolonged outbreak of fluoroquinolone resistant salmonella infection was associated with two nursing homes and a hospital in Portland, Oregon (1). The outbreak came to light in February 1997, when three cases of Salmonella enterica serotype Schwarzengrund infection were linked to a nursing home, where two were current and one was a former resident. Subsequent retesting, interviews with medical staff and reviews of charts and death certificates, and a case control study revealed a larger outbreak. Eleven patients with fluoroquinolone resistant salmonellosis were identified in two nursing homes, nine in one and two in another.

Isolates shared resistance to at least three antimicrobials and had similar pulsed field gel electrophoresis patterns, which were also similar to that of the only previous isolate of S. enterica serotype Schwarzengrund in the United States (isolated in New York in 1995, from a patient who had previously been an inpatient in the Philippines). The nine isolates submitted to polymerase chain reaction of the gyrA gene also shared the same mutations as the 1995 isolate. The index case in this outbreak had also been in the same hospital in the Philippines (transferred to the US in December 1995 and found to be infected two months later.

Spread of infection in the nursing homes is believed to have been from person to person or through contact with infected surfaces. In the case control study four of five cases of salmonellosis compared with two of 13 controls had received fluoroquinolones in the precious six months.

The authors note that the prevalence of fluoroquinolone resistance in nontyphoidal salmonella in the Philippines rose from 2.5% in 1992 and 1993 to 4.7% in 1998. They suggest that the availability of fluoroquinolones over-the-counter and their use in livestock may have contributed to the emergence of resistance in the Philippines.

References :
  1. Olsen SJ, DeBess EE, McGivern TE, Marana N, Eby T, Mauvais S, et al. A nosocomial outbreak of fluoroquinolone-resistant salmonella infection. N Engl J Med 2001; 344: 1572-9. (http://content.nejm.org/cgi/content/abstract/344/21/1572)

Reported by Stuart Handysides (stuart_handysides@hotmail.com), Eurosurveillance editorial office.

back to top



Back to Table of Contents
Previous
Next

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN 1560-7917] - ©2007-2016. All rights reserved.
 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.